English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

UMEZAWA et al. found that forphenicine, isolated from culture filtrates of Actinomycetes fulvoviridis var. acarbodicus is a specific inhibitor against chicken intestine alkaline phosphatase and it was shown to enhance delayed type hypersensitivity and antibody formation in mice1,2). Thereafter, ISHIZUKA et al. found that forphenicinol, a synthetic derivative of forphenicine, enhanced delayed type hypersensitivity and caused macrophage activation by oral administration3). Forphenicinol was also shown to exert an antitumor action and to exhibit a protective effect against an experimental Pseudomonas infection by mortality study'). The present work was designed to study the precise action of forphenicinol against Pseudomonas septicaemia in mice. Female, specific pathogen free ICR mice were obtained from Shizuoka Laboratory Animal Agriculture Cooperative Association, Shizuoka, Japan. Sevento ten-week old mice were used throughout the experiments. Forphenicinol was kindly provided by Dr. H. UMEZAWA and Dr. S. OKA, Institute of Microbial Chemistry, Tokyo, Japan. It was prepared by Banyu Pharmaceutical Co., Ltd., Japan. It was dissolved in sterile saline and was administered orally in a volume of 0.1 ml. Pseudomonas aeruginosa (strain NC-5) was provided originally by Dr. J. Y. HOMMA (Institute of Medical Science, Tokyo University, Japan). This strain was highly virulent for mice and produced neither exotoxin, protease nor lecithinase. Bacterial suspensions were made as described previously5). Mice were infected iv with the dose slightly higher than the LD50 in a volume of 0.1 ml. Challenged mice were observed for 7 days following infection. Bacterial enumeration in the kidneys was performed as described previously5). The viable counts were expressed in log10 units. Bactericidal assay of peripheral blood was carried out as described previously6). Briefly, a mixture of 0.5 ml of heparinized blood and 0.2 ml of the Pseudomonas suspension was rotated 150 rpm on a Gyrotory at 37°C for 3 hours. Three hours after incubation, 0.1 ml of the mixture was serially diluted with distilled water and plated on nutrient agar. Bacterial count was carried out after incubation at 37°C for 24 hours. Nitroblue-tetrazolium (NBT) reduction in casein-induced peritoneal cells was performed Fig. 1. Percent survival of forphenicinol (FP)treated mice infected with P. aeruginosa. Normal controls and forphenicinol-treated mice which had received the doses indicated of forphenicinol daily for 5 days were infected iv with 5.8 x 107 P. aeruginosa. Each group consisted of 10 mice.

Immunopotentiation with forphenicinol: Increased resistance to Pseudomonas septicaemia in mice.